---
title: hodgkin lymphoma (HL)
alias: HL
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[lymphoma and CLL]]

# hodgkin lymphoma (HL)

(Am J Hematol 2018;93:704; Lancet 2021;398:1518)

## Epidemiology and risk factors

- Represents ~12% of lymphomas
- ~8-9K cases annually in US, resulting in ~1300 deaths
- Typically affects younger pts (20s-30s) but can also affect older adults
- ~9,000 cases/y;
- bimodal (15-35 & >50 y)
- â†‘ â™‚
- EBV in of HL,

  - esp. immunocompromised (eg, HIV)

- [[pathology of hodgkin lymphoma (HL)]]
- [[WHO Histologic Classification of Classical HL]]
- [[treatment of hodgkin lymphoma (HL)]]


## Hallmark Study Recently
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). Journal of Clinical Oncology. Published 2023. Accessed January 21, 2024. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4
â€Œ
- [[swog s1826.md|SWOG S1826]]
